Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?-Reference-Cited by-同舟云学术

Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?

Published:2023-03-23 Issue:4 Volume:64 Page:503-504
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Barthel Henryk

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference14 articles.

1. FDA grants accelerated approval for Alzheimer’s disease treatment. FDA website. www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment. January 6, 2023. Accessed March 6, 2023.

2. The role of positron emission tomography imaging in understanding Alzheimer’s disease;Barthel;Expert Rev Neurother.,2015

3. Lecanemab in early Alzheimer’s disease;van Dyck;N Engl J Med.,2023

4. Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain

5. Lecanemab for Alzheimer’s disease: tempering hype and hope (editorial). The Lancet. 2022;400:P1899.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ApoE Mimic Peptide COG1410 Reduces Aβ Deposition and Improves Cognitive Function by Inducing the Transformation of A1/A2 Reactive Astrocytes and Increasing the BDNF Concentration in Brain of APP/PS1 Double Transgenic Mice;Neuroscience;2024-01

2. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials;Frontiers in Aging Neuroscience;2023-05-05